《养心氏片治疗冠心病临床应用专家共识》解读

传统中成药的临床使用历史悠久,应用广泛,具有性质稳定、疗效确切、不良反应小、服用及携带方便等特点。但是源于历史的原因,中成药临床应用面临较多现实问题。认真梳理传统中成药的临床前研究、系统评价上市后研究的相关文献、分析药物不良反应的相关信息,同时结合现代医学研究的最新进展与相关领域专家的临床经验,制定临床应用专家共识,成为指导临床医生更加精准、更加安全、更加广泛地应用传统中成药的重要途径。养心氏片由上海医药集团青岛国风药业股份有限公司研制生产,是具有独立知识产权的中成药制剂(国药准字Z37021102),收录于《中华人民共和国药典》(2015年版)。由世界中医药学会联合会心血管病专业委员会、介入心脏病专业委员会、心脏康复专业委员会,以及中华中医药学会心血管病分会、中国中西医结合学会心血管病专业委员会、中国中医药研究促进会心血管专业委员会共同发起,组织国内中医、西医及中西医结合心血管病专家,历时近2年,对养心氏片组方基础、药理作用、临床研究、安全性数据,进行系统回顾与总结,讨论并起草了《养心氏片治疗冠心病临床应用专家共识》。作者对共识的核心内容做进一步解读。

Interpretation of Consensus of Experts on Clinical Application of Yangxinshi Tablets in Treatment of Coronary Heart Disease

Traditional Chinese patent medicine has a long history of clinical use.It is widely used,with characteristics of stable nature,accurate efficacy,small side effects,easy to take and carry,etc.However,due to historical reasons,there are many practical problems in the clinical application of Chinese patent medicine.Carefully combing preclinical research of Chinese patent medicine,systematically evaluating relevant literature of post-marketing research,analyzing relevant information of adverse drug reactions,combining the latest progress of modern medical research and clinical experience of experts in related fields,and formulating consensus of experts in clinical application have become the key to guide clinicians to use traditional Chinese patent medicine more accurately,safely and widely.Yangxinshi Tablets,developed and produced by Qingdao Growful Pharmaceutical Co.,Ltd.,Shanghai Pharma,is a preparation of Chinese patent medicine(SDFA Approval No.Z37021102)with independent intellectual property rights,included in Pharmacopoeia of the People''s Republic of China(2015 edition).Sponsored jointly by Professional Committee on Cardiovascular Diseases,Professional Committee on Interventional Cardiology and Professional Committee on Cardiac Rehabilitation of World Federation of Chinese Medicine Societies(WFCMS),Cardiovascular Disease Branch of Chinese Association of Chinese Medicine,Professional Committee on Cardiovascular Diseases of Chinese Association of Integrative Medicine,and Cardiovascular Professional Committee of Chinese Association for Research and Advancement of Chinese Medicine,experts of traditional Chinese medicine,western medicine and integrated traditional Chinese and western medicine in cardiovascular diseases were organized and they spent nearly 2 years to systematically review and summarize the formulation basis,pharmacological effect,clinical research and safety data of Yangxinshi Tablets,discussing and drafting Consensus of Experts on Clinical Application of Yangxinshi Tablets in Treatment of Coronary Heart Disease.The author further interprets the core content of the consensus.